Erasca (Erasca) Momentum Rank : 0 (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Erasca Momentum Rank?

Erasca has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Erasca Momentum Rank Related Terms

Thank you for viewing the detailed overview of Erasca's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Erasca (Erasca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121

Website

https://www.erasca.com

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Executives

Jonathan E Lim	director, 10 percent owner, officer: See Remarks	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding	director	C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Shannon Morris	officer: Chief Medical Officer	C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner	officer: General Counsel	C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Lim Conyee T.	10 percent owner	C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121
Arch Venture Fund X, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631